CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer: Suzhou, China Tuesday, March 25, 2025, 17:00 Hrs [IST] C ...

Immutep (ASX:IMM) has dosed the first patient in its pivotal Phase III trial evaluating eftilagimod alfa (efti) for the ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

CStone Pharmaceuticals ('CStone', HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Title: TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell cancer ...

Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Actinium Pharmaceuticals, Inc. (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials studying Actimab-A in ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.